Direct measurement of the anti-influenza agent zanamivir in the respiratory tract following inhalation

Antimicrob Agents Chemother. 2000 Jul;44(7):1974-6. doi: 10.1128/AAC.44.7.1974-1976.2000.

Abstract

In a single-center, randomized study, zanamivir (Relenza) concentrations in induced sputum samples and nasal washings of healthy adults following oral inhalation were measured. Concentrations in sputum exceeded the median viral neuraminidase 50% inhibitory concentration at 6, 12, and 24 h, and those in nasal washings did so at 6 and 12 h. There were no zanamivir-related adverse events or laboratory abnormalities.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Administration, Inhalation
  • Adult
  • Antiviral Agents / adverse effects
  • Antiviral Agents / pharmacokinetics*
  • Female
  • Guanidines
  • Humans
  • Male
  • Nasal Lavage Fluid
  • Neuraminidase / antagonists & inhibitors
  • Orthomyxoviridae / drug effects
  • Orthomyxoviridae / enzymology
  • Pyrans
  • Respiratory System / metabolism*
  • Sialic Acids / adverse effects
  • Sialic Acids / pharmacokinetics*
  • Sputum / metabolism
  • Zanamivir

Substances

  • Antiviral Agents
  • Guanidines
  • Pyrans
  • Sialic Acids
  • Neuraminidase
  • Zanamivir